Single cell omics business is a rapidly growing branch of biotechnology, which involves the study of molecular traits of single cells rather than groups and aggregates of cells.

The Sirolimus market on the other hand is more general referring to the global market in regard to the manufacture, distribution, and sales of the chemical compound sirolimus called rapamycin. Sirolimus is in the category of immunosuppressive drugs which are most commonly used in clients who have undergone transplantation and have organ rejection tendency and used in different types of cancer. It has involved stakeholder groups in the pharmaceutical industry including manufacturers and developers of sirolimus, investigation and research organizations, healthcare facilities and providers, and regulatory organizations. Limiting factors for this market include technological innovations, research and development projects, government dictates in health care, existing legislations, and the experience of organ transplantation and cancer across the globe.